Mantle cell lymphoma (MCL) is characterized by the chromosomal translocation t(11;14)(q13-3; q32-33), resulting in over-expression of the cell cycle protein, cyclin D1. MCL was only recognized as a separate entity in the 1990s. Novel targeted therapies have been approved for the treatment of MCL, however, many patients relapse and have a poor prognosis.